Another name for tirzepatide — and why it matters which one you see

How a medicine ends up with two names, and what the trial evidence behind tirzepatide's showed

Every licensed medicine carries two identities. The international non-proprietary name (INN), assigned by the World Health Organization, belongs to the molecule itself and travels across every country and every manufacturer. The brand name belongs to the company that developed it. For tirzepatide, that company is Eli Lilly, and the brand they chose for the UK, Europe and beyond is Mounjaro.

The clinical programme that brought this medicine to approval used the INN throughout. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity (and no diabetes) and found average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks. Those results were published under the name tirzepatide; the pen that delivered each dose was what became Mounjaro.

Knowing this is useful in a practical sense. If you read a news story citing "tirzepatide" results and a pharmacy talks about "Mounjaro", they are describing the same evidence base and the same physical product. The brand name Mounjaro is simply tirzepatide in its dispensed, packaged form. Nothing is hidden in the name difference.

Zepbound, and other tirzepatide names you may have encountered

If you have been searching this topic, you have probably also come across Zepbound. This is the US brand name for tirzepatide when licensed specifically for weight management in America. It does not exist as a UK product. In the United Kingdom, tirzepatide is licensed for both weight management and type 2 diabetes under a single brand: Mounjaro. Zepbound packaging, Zepbound pricing and Zepbound prescribing information are not applicable here, and any seller offering something labelled Zepbound in the UK is not operating through the licensed UK supply chain.

The various names tirzepatide goes by globally can create genuine confusion. Some people also encounter the INN in NICE documents, for instance, NICE technology appraisal TA1026 recommends tirzepatide for eligible adults with obesity and a weight-related comorbidity, using the INN throughout its recommendations. The medicine those recommendations describe is dispensed in UK pharmacies as Mounjaro.

It is worth mentioning Ozempic and Rybelsus here too. Both contain semaglutide, a different molecule, and both are licensed for type 2 diabetes rather than weight management. They are not another name for tirzepatide, and they should not be sought out as alternatives through that lens.

What the Mounjaro KwikPen actually contains, and the dual-mechanism that makes tirzepatide distinct

The reason tirzepatide generated significant clinical interest is its dual action. Most GLP-1 medicines work on a single receptor pathway; tirzepatide activates both the GIP and GLP-1 receptors involved in appetite regulation and blood-sugar control. The tirzepatide mechanism slows gastric emptying and increases the sense of fullness after meals. No other weight-management medicine licensed in the UK shares this dual-receptor profile.

The Mounjaro KwikPen comes in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Treatment begins at 2.5 mg because the first weeks are an adjustment period for the body, not a therapeutic target. A prescriber, reviewing progress and tolerance, guides any step up from there. The pen itself stores in the fridge door alongside other injectables, and each pen contains four weekly doses. The NHS medicines page for tirzepatide covers storage and handling requirements in full, including the limited window the pen can spend at room temperature before use, always check the patient information leaflet for the exact figures.

For anyone researching Mounjaro's other names before deciding whether to explore treatment, understanding the brand-versus-INN distinction means you can read clinical guidance, news coverage and prescription documentation with confidence.

Eligibility and what comes next if you are considering tirzepatide

NICE TA1026 sets NHS eligibility at BMI 35 or above with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes or obstructive sleep apnoea, with lower BMI thresholds applying for certain ethnic backgrounds. Private eligibility under the Mounjaro SmPC is somewhat broader: adults with a BMI of 30 or above, or 27 or above alongside a qualifying weight-related condition.

Neither threshold is a guarantee. A prescriber assesses the full clinical picture, including medications, medical history and suitability, before approving any treatment. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not automated software. If you want to understand what treatment might look like for you, the weight-loss treatment overview sets out the options, and there is more context on UK costs on the Mounjaro price comparison page. When you are ready, you can start your free consultation and have your answers reviewed by one of our prescribers the same day.